Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences High-Value Diagnostics

Sandra Gaston's Biography



Sandra Gaston, Director, Molecular Biomarkers Research Laboratory; Scientific Director, Tufts Medical Center Biorepository, Tufts Medical Center

Professor Gaston received her Ph.D. from Duke University. After a postdoctoral fellowship at MIT, Professor Gaston held a number of academic positions. Currently Professor Gaston is Director, Molecular Biomarkers Research Laboratory; Scientific Director, Tufts Medical Center Biorepository, and Professor in the Department of Pathology and Laboratory Medicine
Tufts Medical Center.

Sandra Gaston Image

Tissue Print Technologies: An Innovative and Practical Approach to Obtaining High-quality Research Samples from Biopsies and Other Challenging Biospecimens

Tuesday, 17 November 2015 at 08:30

Add to Calendar ▼2015-11-17 08:30:002015-11-17 09:30:00Europe/LondonTissue Print Technologies: An Innovative and Practical Approach to Obtaining High-quality Research Samples from Biopsies and Other Challenging BiospecimensSELECTBIOenquiries@selectbiosciences.com

Development of liquid biopsy technologies for use in the clinical management of cancer patients often requires comparisons with tumor tissues.  Most human tissue samples obtained from clinical biopsy and surgical resections are only secondarily considered as research specimens, and any plan to collect tissue for research must put first priority on patient care. Remnant tissues obtained from fresh surgical specimens are the mainstay for biorepositories that provide high quality snap-frozen tissues for research, but many critical areas of a surgical resection and most diagnostic biopsies cannot be easily “divvied up” before the tissue is submitted for processing as a formalin-fixed paraffin embedded (FFPE) specimen. Moreover, access to FFPE biospecimens for research is becoming more restricted as clinical molecular testing places increasing demands on those tissue blocks. Our research group has developed a set of tissue print technologies that offer an innovative and practical approach to obtaining high quality RNA and DNA from biopsies and other “high value” specimens without compromising pathology diagnosis. Application of these technologies for cancer biomarker discovery and potential clinical diagnostic applications will be discussed.


Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonHigh-Value DiagnosticsSELECTBIOenquiries@selectbiosciences.com